newsfilter
← Latest News
GlobeNewswire·

Femasys Announces Third Quarter Financial Results for 2025

– FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway – ATLANTA, Nov. 14, 2025